Efficacy and safety of Ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20).
Affiliation
Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, USA.Issue Date
2013-10
Metadata
Show full item recordAbstract
In a phase III trial (ClinicalTrials.gov registration ID: NCT00094653), ipilimumab significantly improved survival versus a vaccine control in pretreated patients with metastatic melanoma. Here, we characterize outcomes of those patients who survived ≥ 2 years.Citation
Efficacy and safety of Ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). 2013, 24 (10):2694-8 Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdt291PubMed ID
23942774Type
ArticleLanguage
enISSN
1569-8041ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdt291
Scopus Count
Collections
Related articles
- Improved survival with ipilimumab in patients with metastatic melanoma.
- Authors: Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ
- Issue date: 2010 Aug 19
- Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment.
- Authors: Revicki DA, van den Eertwegh AJ, Lorigan P, Lebbe C, Linette G, Ottensmeier CH, Safikhani S, Messina M, Hoos A, Wagner S, Kotapati S
- Issue date: 2012 Jun 13
- CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma.
- Authors: Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ
- Issue date: 2012 Apr 1
- Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control.
- Authors: Robert C, Schadendorf D, Messina M, Hodi FS, O'Day S, MDX010-20 investigators.
- Issue date: 2013 Apr 15
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
- Authors: Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor DR, Salama AK, Taylor MH, Ott PA, Horak C, Gagnier P, Jiang J, Wolchok JD, Postow MA
- Issue date: 2016 Nov